Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology : WJG - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Human papillomavirus bowel colonization in inflammatory bowel disease: A comparative case control study
CONCLUSIONS: There was no evidence of HPV ileocolonic colonization in this cohort of patients with IBD, regardless of disease activity. HPV colonization does not appear to be linked to IBD diagnosis or disease severity.PMID:35800585 | PMC:PMC9254796 | DOI:10.4103/jfmpc.jfmpc_1871_21 (Source: Primary Care)
Source: Primary Care - July 8, 2022 Category: Primary Care Authors: Mahmoud H Mosli Marwan Albeshri Mohammad N Alsanea Turki AlAmeel Haneen Alabsi Majid Alsahafi Omar Saadah Yousef Qari Source Type: research

Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a < em > Cryptosporidium hominis < /em > outbreak
CONCLUSIONS: The incidence of late-onset IBD and MC increased after the Cryptosporidium outbreak. Cryptosporidiosis may be an environmental risk factor for IBD and MC.PMID:35802626 | DOI:10.1080/00365521.2022.2094722 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Marije Boks Mikael Lilja Micael Widerstr öm Pontus Karling Anna Lindam Axel Eriksson Malin Sj öström Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology : WJG - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Human papillomavirus bowel colonization in inflammatory bowel disease: A comparative case control study
CONCLUSIONS: There was no evidence of HPV ileocolonic colonization in this cohort of patients with IBD, regardless of disease activity. HPV colonization does not appear to be linked to IBD diagnosis or disease severity.PMID:35800585 | PMC:PMC9254796 | DOI:10.4103/jfmpc.jfmpc_1871_21 (Source: Primary Care)
Source: Primary Care - July 8, 2022 Category: Primary Care Authors: Mahmoud H Mosli Marwan Albeshri Mohammad N Alsanea Turki AlAmeel Haneen Alabsi Majid Alsahafi Omar Saadah Yousef Qari Source Type: research

Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a < em > Cryptosporidium hominis < /em > outbreak
CONCLUSIONS: The incidence of late-onset IBD and MC increased after the Cryptosporidium outbreak. Cryptosporidiosis may be an environmental risk factor for IBD and MC.PMID:35802626 | DOI:10.1080/00365521.2022.2094722 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Marije Boks Mikael Lilja Micael Widerstr öm Pontus Karling Anna Lindam Axel Eriksson Malin Sj öström Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology : WJG - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Human papillomavirus bowel colonization in inflammatory bowel disease: A comparative case control study
CONCLUSIONS: There was no evidence of HPV ileocolonic colonization in this cohort of patients with IBD, regardless of disease activity. HPV colonization does not appear to be linked to IBD diagnosis or disease severity.PMID:35800585 | PMC:PMC9254796 | DOI:10.4103/jfmpc.jfmpc_1871_21 (Source: Primary Care)
Source: Primary Care - July 8, 2022 Category: Primary Care Authors: Mahmoud H Mosli Marwan Albeshri Mohammad N Alsanea Turki AlAmeel Haneen Alabsi Majid Alsahafi Omar Saadah Yousef Qari Source Type: research

Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a < em > Cryptosporidium hominis < /em > outbreak
CONCLUSIONS: The incidence of late-onset IBD and MC increased after the Cryptosporidium outbreak. Cryptosporidiosis may be an environmental risk factor for IBD and MC.PMID:35802626 | DOI:10.1080/00365521.2022.2094722 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Marije Boks Mikael Lilja Micael Widerstr öm Pontus Karling Anna Lindam Axel Eriksson Malin Sj öström Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology : WJG - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research

Updates in therapeutic drug monitoring in inflammatory bowel disease
World J Gastroenterol. 2022 Jun 7;28(21):2282-2290. doi: 10.3748/wjg.v28.i21.2282.ABSTRACTBiologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologi...
Source: World Journal of Gastroenterology : WJG - July 8, 2022 Category: Gastroenterology Authors: Nilesh Lodhia Shanti Rao Source Type: research